Online Only
Clinical trial recruitment and retention remain challenging in the quest to bring innovative therapies to all patients in need.
The conversation around work-life balance in healthcare can sometimes feel like a luxury, or worse, a myth. But in oncology pharmacy, balance isn’t about perfection or strict boundaries; it’s about sustainability.
Original Research, Adverse Events, Disparities in Oncology, Dose Escalation/Reduction, Immunotherapy, Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy in the United States and Europe.
Laura Fan Sun, PharmD, BCOP; Natalie Brumwell, PharmD; Kevin Hall, PharmD; Kristina Murphy, PharmD; Jeffrey Switchenko, PhD; Yichun Cao, MPH; Vikas Gupta, MD, PhD; Madhav Dhodapkar, MBBS; Nisha Joseph, MD; Craig Hofmeister, MD, MPH; Jonathan Kaufman, MD; Ajay Nooka, MD, MPH, FACP; Sagar Lonial, MD; Kathryn Maples, PharmD
With major reimbursement and coverage changes occurring in 2026, oncology practices are closely watching federal policy developments that could affect everything from prior authorization workflows to drug reimbursement and patient coverage stability.
Researchers and clinical investigators are facing a series of unprecedented challenges as they adjust to necessary changes to their work environment resulting from the COVID-19 crisis. In this discussion, moderated by Rob Butcher, CEO, Swim Across America, a panel of researchers discuss the impact of the pandemic on conditions in laboratories, and how graduate students have had to adjust to interruptions in their career trajectories.
Telehealth continues to play a critical role in providing healthcare services to patients during the COVID-19 pandemic. In a webcast titled COVID-19: Impact on Telehealth, Rick Lee, Executive Chairman, Healthy Platforms and CancerLife, along with a panel of experts, discussed the benefits and ongoing challenges associated with the use of telemedicine and the far-reaching impact of this technology beyond the current crisis.
Employers continue to face significant challenges as they strive to provide healthcare coverage for their employees during the COVID-19 pandemic. In this discussion, moderated by Burt Zweigenhaft, PhD, D.Litt, a panel of experts explore solutions for some of the issues arising in a vastly changed healthcare market, and strategies for improving the way in which health benefits are conceived and implemented.
Pharmaceutical support and innovation are vital to the effective treatment of patients with cancer. In this discussion, moderated by Burt Zweigenhaft, PhD, D.Litt, a panel of experts discussed the importance of maintaining an adequate supply of medicines for patients, and the need for philanthropic programs to ensure patients will be able to continue their medications, even if they lose their health insurance.
As a result of the ongoing COVID-19 pandemic, comprehensive cancer care centers have been tasked with significantly altering their strategies for the delivery of care. In this discussion, moderated by Burt Zweigenhaft, PhD, D.Litt, a panel of experts discuss some of the changes that have already been implemented at their centers and future considerations for healthcare systems as they focus on providing safe and effective care on the road to recovery.
Issues surrounding healthcare insurance continue to unfold in light of the recent COVID-19 pandemic. In this discussion, a panel of managed care experts, moderated by Michael Kolodziej, MD, explore strategies for reducing the total cost of care for patients with cancer and addressing the economic and administrative burdens that practices and payers are facing as a result of the crisis.